Skip to Content
Vicki L.  Keedy

Vicki L. Keedy, M.D., MSCI

Assistant Professor of Medicine (Hematology/Oncology)
Clinical Director, Sarcoma
Medical Director, Clinical Trials Shared Resource
Medical Oncologist

  • Appointments
    Physicians: 1-877-936-8422
  • Clinical Trials Information
  • Other Telephone Numbers
    Henry-Joyce Cancer Clinic
    (615) 936-8422 or 1 (877) 936-8422

  • Faxes
    Henry-Joyce Cancer Clinic Fax
    (615) 343-8668
    Office Fax
  • Addresses
    Henry-Joyce Cancer Clinic
    1301 Medical Center Drive, Suite 1710
    Nashville, Tennessee 37232-7415

    2220 Pierce Avenue
    777 Preston Research Building
    Nashville, TN 37232-6307

Dr. Keedy is an Assistant Professor of Medicine in the Division of Hematology/Oncology. After receiving her B.S. in Microbiology at Indiana University, she went to medical school at the University of Cincinnati. Dr. Keedy completed her Internal Medicine Residency and Hematology/Oncology training at Vanderbilt University Medical Center. She is a graduate of the Master of Science in Clinical Investigation Program at Vanderbilt.

Dr. Keedy is the Clinical Director for Sarcoma, a member of the Phase I Clinical Trial team, and serves as the principal investigator on several soft tissue sarcoma, bone sarcoma, GIST, and Phase I clinical trials. She is a member of the Sarcoma Alliance for Research Collaboration, and is a member of the AJCC Soft Tissue Sarcoma Expert Panel.

She is active in the American Society of Clinical Oncology, and has served on the Career Development and Health Services Committees. In her role as the Medical Director for the Clinical Trials Shared Resource, she serves on the AACI/Clinical Research Initiative working group.

  •          University of Cincinnati College of Medicine, M.D.
  •          Residency/Fellowship: Vanderbilt University Medical Center
  •          Master of Science in Clinical Investigation, Vanderbilt University School of Medicine, 2009
  • Grilley-Olson JE, Keedy VL, Sandler A, Moore DT, Socinski MA, Stinchcombe TE. A randomized phase II study of carboplatin with weekly or every-3-week nanoparticle albumin-bound paclitaxel (abraxane) in patients with extensive-stage small cell lung cancer. Oncologist [print-electronic]. 2015 Feb; 20(2): 105-6. PMID: 25616430, PMCID: PMC4319632, PII: theoncologist.2014-0327, DOI: 10.1634/theoncologist.2014-0327, ISSN: 1549-490X.
    Available from:
  • Wu H, Infante JR, Keedy VL, Jones SF, Chan E, Bendell JC, Lee W, Kirschbrown WP, Zamboni BA, Ikeda S, Kodaira H, Rothenberg ML, Burris HA, Zamboni WC. Factors affecting the pharmacokinetics and pharmacodynamics of PEGylated liposomal irinotecan (IHL-305) in patients with advanced solid tumors. Int J Nanomedicine. 2015; 10: 1201-9. PMID: 25709442, PMCID: PMC4334335, PII: ijn-10-1201, DOI: 10.2147/IJN.S62911, ISSN: 1178-2013.
    Available from:
  • Johnson DB, Dahlman KH, Knol J, Gilbert J, Puzanov I, Means-Powell J, Balko JM, Lovly CM, Murphy BA, Goff LW, Abramson VG, Crispens MA, Mayer IA, Berlin JD, Horn L, Keedy VL, Reddy NM, Arteaga CL, Sosman JA, Pao W. Enabling a genetically informed approach to cancer medicine: a retrospective evaluation of the impact of comprehensive tumor profiling using a targeted next-generation sequencing panel. Oncologist [print-electronic]. 2014 Jun; 19(6): 616-22. PMID: 24797823, PMCID: PMC4041676, PII: theoncologist.2014-0011, DOI: 10.1634/theoncologist.2014-0011, ISSN: 1549-490X.
    Available from:
  • Lammers PE, Shyr Y, Li CI, Hutchison AS, Sandler A, Carbone DP, Johnson DH, Keedy VL, Horn L. Phase II study of bendamustine in relapsed chemotherapy sensitive or resistant small-cell lung cancer. J Thorac Oncol. 2014 Apr; 9(4): 559-62. PMID: 24736081, PMCID: PMC3990869, PII: 01243894-201404000-00024, DOI: 10.1097/JTO.0000000000000079, ISSN: 1556-1380.
    Available from:
  • Stevens PL, Johnson DB, Thompson MA, Keedy VL, Frangoul HA, Snyder KM. Adult neuroblastoma complicated by increased intracranial pressure: a case report and review of the literature. Case Rep Oncol Med [print-electronic]. 2014; 2014: 341980. PMID: 25328733, PMCID: PMC4190830, DOI: 10.1155/2014/341980, ISSN: 2090-6706.
    Available from:
  • Cate F, Bridge JA, Crispens MA, Keedy VL, Troutman A, Coffin CM, Fadare O. Composite uterine neoplasm with embryonal rhabdomyosarcoma and primitive neuroectodermal tumor components: rhabdomyosarcoma with divergent differentiation, variant of primitive neuroectodermal tumor, or unique entity?. Hum. Pathol [print-electronic]. 2013 Apr; 44(4): 656-63. PMID: 23266445, PII: S0046-8177(12)00336-X, DOI: 10.1016/j.humpath.2012.09.008, ISSN: 1532-8392.
    Available from:
  • Abramson RG, Abramson VG, Chan E, Horn L, Keedy VL, Pao W, Sosman JA. Complications of targeted drug therapies for solid malignancies: manifestations and mechanisms. AJR Am J Roentgenol. 2013 Mar; 200(3): 475-83. PMID: 23436834, PMCID: PMC3652983, PII: 200/3/475, DOI: 10.2214/AJR.12.9049, ISSN: 1546-3141.
    Available from:
  • Horn L, Keedy VL, Campbell N, Garcia G, Hayes A, Spencer B, Carbone DP, Sandler A, Johnson DH. Identifying barriers associated with enrollment of patients with lung cancer into clinical trials. Clin Lung Cancer [print-electronic]. 2013 Jan; 14(1): 14-8. PMID: 22591607, PII: S1525-7304(12)00075-7, DOI: 10.1016/j.cllc.2012.03.008, ISSN: 1938-0690.
    Available from:
  • Mignemi NA, Itani DM, Fasig JH, Keedy VL, Hande KR, Whited BW, Homlar KC, Correa H, Coffin CM, Black JO, Yi Y, Halpern JL, Holt GE, Schwartz HS, Schoenecker JG, Cates JM. Signal transduction pathway analysis in desmoid-type fibromatosis: transforming growth factor-ß, COX2 and sex steroid receptors. Cancer Sci [print-electronic]. 2012 Dec; 103(12): 2173-80. PMID: 23035734, PMCID: PMC4278584, DOI: 10.1111/cas.12037, ISSN: 1349-7006.
    Available from:
  • Cates JM, Black JO, Itani DM, Fasig JH, Keedy VL, Hande KR, Whited BW, Homlar KC, Halpern JL, Holt GE, Schwartz HS, Coffin CM. Signal transduction pathway analysis in fibromatosis: receptor and nonreceptor tyrosine kinases. Hum. Pathol [print-electronic]. 2012 Oct; 43(10): 1711-8. PMID: 22520949, PMCID: PMC4278590, PII: S0046-8177(11)00530-2, DOI: 10.1016/j.humpath.2011.12.021, ISSN: 1532-8392.
    Available from:
  • Kallen ME, Sanders ME, Gonzalez AL, Black JO, Keedy VL, Hande KR, Homlar KC, Halpern JL, Holt GE, Schwartz HS, Coffin CM, Cates JM. Nuclear p63 expression in osteoblastic tumors. Tumour Biol [print-electronic]. 2012 Oct; 33(5): 1639-44. PMID: 22623071, DOI: 10.1007/s13277-012-0419-y, ISSN: 1423-0380.
    Available from:
  • Cates JM, Black J, Wolfe CC, Shinohara ET, Holt GE, Keedy VL, Hande KR, Homlar KC, Halpern JL, Schwartz HS, Troutman A, Coffin CM. Morphologic and immunophenotypic analysis of desmoid-type fibromatosis after radiation therapy. Hum. Pathol [print-electronic]. 2012 Sep; 43(9): 1418-24. PMID: 22404950, PII: S0046-8177(11)00462-X, DOI: 10.1016/j.humpath.2011.11.002, ISSN: 1532-8392.
    Available from:
  • Keedy VL. Treating metastatic soft-tissue or bone sarcomas - potential role of ridaforolimus. Onco Targets Ther [print-electronic]. 2012; 5: 153-60. PMID: 22942649, PMCID: PMC3428242, PII: ott-5-153, DOI: 10.2147/OTT.S19055, ISSN: 1178-6930.
    Available from:
  • Keedy VL, Temin S, Somerfield MR, Beasley MB, Johnson DH, McShane LM, Milton DT, Strawn JR, Wakelee HA, Giaccone G. American Society of Clinical Oncology provisional clinical opinion: epidermal growth factor receptor (EGFR) Mutation testing for patients with advanced non-small-cell lung cancer considering first-line EGFR tyrosine kinase inhibitor therapy. J. Clin. Oncol [print-electronic]. 2011 May 5/20/2011; 29(15): 2121-7. PMID: 21482992, PII: JCO.2010.31.8923, DOI: 10.1200/JCO.2010.31.8923, ISSN: 1527-7755.
    Available from:
  • Tatsas AD, Keedy VL, Florell SR, Simpson JF, Coffin CM, Kelley MC, Cates JM. Foamy cell angiosarcoma: a rare and deceptively bland variant of cutaneous angiosarcoma. J. Cutan. Pathol [print-electronic]. 2010 Aug; 37(8): 901-6. PMID: 20175826, PII: CUP1512, DOI: 10.1111/j.1600-0560.2010.01512.x, ISSN: 1600-0560.
    Available from:
  • Moretti L, Yu DS, Chen H, Carbone DP, Johnson DH, Keedy VL, Putnam JB, Sandler AB, Shyr Y, Lu B. Prognostic factors for resected non-small cell lung cancer with pN2 status: implications for use of postoperative radiotherapy. Oncologist [print-electronic]. 2009 Nov; 14(11): 1106-15. PMID: 19897534, PMCID: PMC3045762, PII: theoncologist.2009-0130, DOI: 10.1634/theoncologist.2009-0130, ISSN: 1549-490X.
    Available from:
  • Herceg ME, Tsiatis AC, Halpern JL, Holt GE, Schwartz HS, Keedy VL, Cates JM. Cyclooxygenase 2 expression in soft tissue leiomyosarcoma. Anticancer Res. 2009 Aug; 29(8): 2913-7. PMID: 19661295, PII: 29/8/2913, ISSN: 1791-7530.
    Available from:
  • Keedy VL, Sandler AB. Inhibition of angiogenesis in the treatment of non-small cell lung cancer. Cancer Sci [print-electronic]. 2007 Dec; 98(12): 1825-30. PMID: 17892508, PII: CAS620, DOI: 10.1111/j.1349-7006.2007.00620.x, ISSN: 1349-7006.
    Available from:
  • Keedy VL, Berlin J. Adjuvant and neoadjuvant approaches to treat surgically resectable pancreatic cancer. Curr Treat Options Oncol. 2006 Sep; 7(5): 381-8. PMID: 16904055, ISSN: 1527-2729.
    Available from: